Edition:
United States

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

5.89USD
15 Dec 2017
Change (% chg)

$0.14 (+2.43%)
Prev Close
$5.75
Open
$5.75
Day's High
$6.01
Day's Low
$5.63
Volume
1,126,827
Avg. Vol
227,034
52-wk High
$9.69
52-wk Low
$3.59

Select another date:

Thu, Nov 2 2017

BRIEF-Tetraphase Pharmaceuticals Q3 loss per share $0.63

* Tetraphase pharmaceuticals reports third quarter 2017 financial results and highlights recent clinical and corporate achievements

BRIEF-Tetraphase Pharmaceuticals signs commercial supply agreement with Finorga

* Tetraphase Pharmaceuticals Inc says ‍on October 16 co and finorga sas entered into a commercial supply agreement​ - sec filing

BRIEF-TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CFO

* TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CHIEF FINANCIAL OFFICER

BRIEF-Tetraphase Pharmaceuticals presents clinical data from oral eravacycline development program at IDWEEK 2017​

* Tetraphase Pharmaceuticals - ‍phase 2 trial in patients with complicated urinary tract infections expected to begin in h1 2018​

BRIEF-Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline

* Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline in complicated urinary tract infections

BRIEF-Tetraphase announces validation of IV eravacycline MAA by European Medicines Agency

* Tetraphase Pharmaceuticals announces submission and validation of IV eravacycline marketing authorization application by European Medicines Agency

BRIEF-Tetraphase announces pricing of public offering of common stock

* Tetraphase announces pricing of public offering of common stock

BRIEF-Tetraphase announces proposed public offering of common stock

* Tetraphase announces proposed public offering of common stock

BRIEF-Tetraphase announces positive top-line results from Phase 3 IGNITE4 Clinical Trial

* Tetraphase Pharmaceuticals announces positive top-line results from phase 3 IGNITE4 clinical trial in complicated intra-abdominal infections

Tetraphase's antibiotic succeeds late-stage study, shares soar

Tetraphase Pharmaceuticals Inc said its lead experimental antibiotic for serious bacterial infections met the main goal in a late-stage study, sending its shares surging nearly 23 percent in after-market trading on Tuesday.

Select another date: